CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Seres Therapeutics Inc - MCRB CFD

1.06
3.64%
Market Trading Hours* (UTC) Open now
Closes on Tuesday at 21:00

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026346 %
Charges from full value of position ($-5.01)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026346%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004124 %
Charges from full value of position ($0.78)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Seres Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.1
Open* 1.06
1-Year Change* -85.07%
Day's Range* 1.05 - 1.08
52 wk Range 0.91-7.30
Average Volume (10 days) 3.96M
Average Volume (3 months) 73.54M
Market Cap 135.07M
P/E Ratio -100.00K
Shares Outstanding 129.26M
Revenue 127.24M
EPS -1.13
Dividend (Yield %) N/A
Beta 2.52
Next Earnings Date Mar 5, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 4, 2023 1.10 0.05 4.76% 1.05 1.12 1.02
Dec 1, 2023 1.04 0.05 5.05% 0.99 1.06 0.96
Nov 30, 2023 1.03 -0.08 -7.21% 1.11 1.13 0.99
Nov 29, 2023 1.09 -0.02 -1.80% 1.11 1.18 1.09
Nov 28, 2023 1.10 -0.02 -1.79% 1.12 1.13 1.08
Nov 27, 2023 1.13 0.05 4.63% 1.08 1.14 1.04
Nov 24, 2023 1.12 0.05 4.67% 1.07 1.17 1.07
Nov 22, 2023 1.08 0.03 2.86% 1.05 1.10 0.98
Nov 21, 2023 1.02 -0.04 -3.77% 1.06 1.15 1.01
Nov 20, 2023 0.95 -0.43 -31.16% 1.38 1.38 0.94
Nov 17, 2023 1.39 0.23 19.83% 1.16 1.41 1.14
Nov 16, 2023 1.14 -0.05 -4.20% 1.19 1.20 1.09
Nov 15, 2023 1.18 -0.01 -0.84% 1.19 1.33 1.18
Nov 14, 2023 1.21 0.16 15.24% 1.05 1.21 1.05
Nov 13, 2023 1.04 0.04 4.00% 1.00 1.05 0.96
Nov 10, 2023 0.99 0.02 2.06% 0.97 0.99 0.94
Nov 9, 2023 0.98 -0.05 -4.85% 1.03 1.03 0.90
Nov 8, 2023 1.01 -0.18 -15.13% 1.19 1.19 1.00
Nov 7, 2023 1.19 0.06 5.31% 1.13 1.20 1.05
Nov 6, 2023 1.11 -0.17 -13.28% 1.28 1.30 1.11

Seres Therapeutics Inc Events

Time (UTC) Country Event
Tuesday, March 5, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Seres Therapeutics Inc Earnings Release
Q4 2023 Seres Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 7.128 144.927 33.215 34.505 28.267
Revenue 7.128 144.927 33.215 34.505 28.267
Total Operating Expense 253.618 209.42 121.345 106.381 128.551
Selling/General/Admin. Expenses, Total 85.796 69.261 30.775 24.748 32.596
Research & Development 166.818 141.891 90.57 80.141 95.955
Operating Income -246.49 -64.493 -88.13 -71.876 -100.284
Interest Income (Expense), Net Non-Operating -2.962 -0.04 -1.978 0.531 1.172
Net Income Before Taxes -250.157 -65.578 -89.127 -70.279 -98.942
Net Income After Taxes -250.157 -65.578 -89.127 -70.279 -98.942
Net Income Before Extra. Items -250.157 -65.578 -89.127 -70.279 -98.942
Net Income -250.157 -65.578 -89.127 -70.279 -98.942
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -250.157 -65.578 -89.127 -70.279 -98.942
Income Available to Common Incl. Extra. Items -250.157 -65.578 -89.127 -70.279 -98.942
Diluted Net Income -250.157 -65.578 -89.127 -70.279 -98.942
Diluted Weighted Average Shares 108.077 91.7029 79.7892 56.6492 40.7435
Diluted EPS Excluding Extraordinary Items -2.31462 -0.71511 -1.11703 -1.2406 -2.42841
Diluted Normalized EPS -2.31462 -0.71511 -1.11703 -1.21426 -2.42841
Other, Net -0.705 -1.045 0.981 1.066 0.17
Total Extraordinary Items 0
Dividends per Share - Common Stock Primary Issue
Unusual Expense (Income) 0 0 1.492
Other Operating Expenses, Total 1.004 -1.732
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 126.473 -0.522 0.975 3.444 1.216
Revenue 126.473 -0.522 0.975 3.444 1.216
Total Operating Expense 76.949 70.046 69.282 62.551 64.541
Selling/General/Admin. Expenses, Total 28.051 22.47 22.404 18.384 20.335
Research & Development 46.792 43.969 46.22 43.116 43.935
Operating Income 49.524 -70.568 -68.307 -59.107 -63.325
Interest Income (Expense), Net Non-Operating -1.461 -0.916 -0.466 -0.862 -1.106
Other, Net -1.511 0.31 -0.023 -0.033 -0.304
Net Income Before Taxes 46.552 -71.174 -68.796 -60.002 -64.735
Net Income After Taxes 46.552 -71.174 -68.796 -60.002 -64.735
Net Income Before Extra. Items 46.552 -71.174 -68.796 -60.002 -64.735
Net Income 46.552 -71.174 -68.796 -60.002 -64.735
Income Available to Common Excl. Extra. Items 46.552 -71.174 -68.796 -60.002 -64.735
Income Available to Common Incl. Extra. Items 46.552 -71.174 -68.796 -60.002 -64.735
Diluted Net Income 46.552 -71.174 -68.796 -60.002 -64.735
Diluted Weighted Average Shares 129.845 125.863 125.166 122.527 92.2554
Diluted EPS Excluding Extraordinary Items 0.35852 -0.56549 -0.54964 -0.4897 -0.70169
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.35852 -0.56549 -0.54964 -0.4897 -0.70169
Other Operating Expenses, Total 2.106 3.607 0.658 1.051 0.271
Unusual Expense (Income)
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 194.764 303.628 268.777 100.189 92.665
Cash and Short Term Investments 181.341 290.706 253.616 94.816 85.82
Cash & Equivalents 163.03 180.002 116.049 65.126 85.82
Short Term Investments 18.311 110.704 137.567 29.69 0
Prepaid Expenses 13.423 12.922 5.774 3.588 6.845
Total Assets 348.784 354.859 342.94 132.44 120.472
Property/Plant/Equipment, Total - Net 133.969 36.146 22.938 30.851 26.294
Property/Plant/Equipment, Total - Gross 179.009 76.414 57.258 58.593 46.595
Accumulated Depreciation, Total -45.04 -40.268 -34.32 -27.742 -20.301
Long Term Investments 0 0.495 49.825
Other Long Term Assets, Total 20.051 14.59 1.4 1.4 1.513
Total Current Liabilities 85.596 82.258 46.415 45.993 42.041
Accounts Payable 17.44 13.735 4.018 4.859 6.415
Accrued Expenses 18.31 15.826 11.849 9.065 5.02
Notes Payable/Short Term Debt 0.456 0 0.454 0 0
Other Current Liabilities, Total 49.39 52.697 30.094 32.069 30.606
Total Liabilities 338.001 223.352 168.19 180.764 168.517
Total Long Term Debt 50.591 24.643 24.639 24.648 0
Other Liabilities, Total 201.814 116.451 97.136 110.123 126.476
Total Equity 10.783 131.507 174.75 -48.324 -48.045
Common Stock 0.125 0.092 0.091 0.07 0.041
Additional Paid-In Capital 875.181 745.829 723.482 411.255 341.284
Retained Earnings (Accumulated Deficit) -864.511 -614.354 -548.776 -459.649 -389.37
Other Equity, Total -0.012 -0.06 -0.047 0
Total Liabilities & Shareholders’ Equity 348.784 354.859 342.94 132.44 120.472
Total Common Shares Outstanding 125.222 91.8894 91.4592 70.1432 40.9367
Redeemable Preferred Stock
Total Receivables, Net 0 9.387 1.785
Accounts Receivable - Trade, Net 0 9.387 1.785
Long Term Debt 50.591 24.643 24.639 24.648
Current Port. of LT Debt/Capital Leases 0
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 214.394 251.238 116.081 194.764 247.513
Cash and Short Term Investments 169.912 229.52 106.544 181.341 233.003
Cash & Equivalents 169.912 229.52 94.841 163.03 205.398
Short Term Investments 0 0 11.703 18.311 27.605
Total Receivables, Net 16.857 7.559
Accounts Receivable - Trade, Net
Prepaid Expenses 9.1 8.819 9.537 13.423 14.51
Total Assets 367.699 406.387 270.194 348.784 311.868
Property/Plant/Equipment, Total - Net 131.671 134.309 133.22 133.969 43.231
Property/Plant/Equipment, Total - Gross 181.322 182.276 179.66 179.009 88.501
Accumulated Depreciation, Total -49.651 -47.967 -46.44 -45.04 -45.27
Long Term Investments 0 0
Other Long Term Assets, Total 21.634 20.84 20.893 20.051 21.124
Total Current Liabilities 79.225 77.898 63.818 85.596 81.819
Accounts Payable 8.958 12.922 12.297 17.44 10.449
Accrued Expenses 19.759 17.158 11.661 18.31 18.114
Notes Payable/Short Term Debt 0 0 0 0.456 0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total 50.508 47.818 39.86 49.39 53.256
Total Liabilities 382.822 383.773 318.065 338.001 244.283
Total Long Term Debt 101.135 100.742 51.234 50.591 50.857
Long Term Debt 101.135 100.742 51.234 50.591 50.857
Other Liabilities, Total 202.462 205.133 203.013 201.814 111.607
Total Equity -15.123 22.614 -47.871 10.783 67.585
Common Stock 0.129 0.128 0.127 0.125 0.124
Additional Paid-In Capital 921.735 911.62 887.685 875.181 863.294
Retained Earnings (Accumulated Deficit) -936.987 -889.133 -935.685 -864.511 -795.715
Other Equity, Total 0 -0.001 0.002 -0.012 -0.118
Total Liabilities & Shareholders’ Equity 367.699 406.387 270.194 348.784 311.868
Total Common Shares Outstanding 128.631 128.038 126.593 125.222 124.411
Total Inventory 18.525 5.34
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -250.157 -65.578 -89.127 -70.279 -98.942
Cash From Operating Activities -228.815 6.688 -93.61 -76.52 -62.854
Cash From Operating Activities 6.629 5.947 6.578 7.603 7.862
Non-Cash Items 33.103 24.789 12.136 10.783 16.427
Cash Interest Paid 4.926 2.446 2.453 0.221 0
Changes in Working Capital -18.39 41.53 -23.197 -24.627 11.799
Cash From Investing Activities 82.428 64.088 -158.891 -30.518 112.318
Capital Expenditures -9.821 -9.566 -0.591 -1.002 -1.937
Other Investing Cash Flow Items, Total 92.249 73.654 -158.3 -29.516 114.255
Cash From Financing Activities 129.602 1.178 303.424 86.231 0.268
Issuance (Retirement) of Stock, Net 103.903 2.126 283.524 61.656 0.268
Net Change in Cash -16.786 71.953 50.923 -20.807 49.732
Financing Cash Flow Items 0 19.9 -0.425
Issuance (Retirement) of Debt, Net 25.699 -0.948 25
Foreign Exchange Effects -0.001 -0.001
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -71.174 -250.157 -181.361 -121.359 -56.624
Cash From Operating Activities -76.584 -228.815 -175.922 -116.342 -66.445
Cash From Operating Activities 1.4 6.629 5.002 3.255 1.57
Non-Cash Items 12.527 33.103 23.324 14.302 5.607
Cash Interest Paid 1.737 4.926 3.282 1.836 0.558
Changes in Working Capital -19.337 -18.39 -22.887 -12.54 -16.998
Cash From Investing Activities 2.739 82.428 76.502 36.371 12.972
Capital Expenditures -4.068 -9.821 -6.36 -5.113 -2.95
Other Investing Cash Flow Items, Total 6.807 92.249 82.862 41.484 15.922
Cash From Financing Activities 5.656 129.602 125.005 26.978 26.848
Issuance (Retirement) of Stock, Net 5.656 103.903 102.585 1.279 1.149
Net Change in Cash -68.189 -16.786 25.583 -52.993 -26.625
Financing Cash Flow Items -3.279
Issuance (Retirement) of Debt, Net 0 25.699 25.699 25.699 25.699
Foreign Exchange Effects -0.001 -0.002
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Flagship Ventures Venture Capital 18.0314 23117045 0 2023-06-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 14.9645 19185208 273750 2023-06-30 LOW
Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund 8.888 11394801 -105719 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 6.6807 8564935 4796626 2023-06-30 LOW
Nestle SA Corporation 5.9234 7594038 -298852 2022-07-18 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.2306 6705853 1327621 2023-06-30 LOW
Janus Henderson Investors Investment Advisor/Hedge Fund 4.7369 6072942 -5227873 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.1596 5332847 -505131 2023-06-30 LOW
Eversept Partners, LP Hedge Fund 2.3999 3076756 540091 2023-06-30 HIGH
Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 1.95 2500000 1205000 2023-06-30 LOW
Soleus Capital Management, L.P. Hedge Fund 1.5959 2045983 2045983 2023-06-30 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.5299 1961358 325849 2023-06-30 LOW
Millennium Management LLC Hedge Fund 1.3727 1759914 1351434 2023-06-30 HIGH
Jennison Associates LLC Investment Advisor/Hedge Fund 1.086 1392356 727622 2023-06-30 LOW
BofA Global Research (US) Research Firm 0.9312 1193896 810048 2023-06-30 LOW
Point72 Asset Management, L.P. Hedge Fund 0.7959 1020400 727600 2023-06-30 HIGH
Handelsbanken Kapitalförvaltning AB Investment Advisor/Hedge Fund 0.78 1000000 0 2023-09-30 LOW
Great Point Partners, LLC Hedge Fund 0.7317 938067 938067 2023-06-30 HIGH
Hudson Bay Capital Management LP Hedge Fund 0.6864 880000 355000 2023-06-30 HIGH
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.6183 792699 160286 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Seres Therapeutics Inc Company profile

About Seres Therapeutics Inc

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis and SER-155 to treat enteric bacterial pathogens.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Seres Therapeutics Inc revenues increased from $33.2M to $144.9M. Net loss decreased 26% to $65.6M. Revenues reflect Collaboration revenue - related party increase from $11.9M to $143.9M. Lower net loss reflects Interest income increase from $946K to $2.9M (income), Interest expense remaining flat at $2.9M (expense).

Industry: Bio Therapeutic Drugs

200 Sidney St
CAMBRIDGE
MASSACHUSETTS 02139-4218
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

Oil - Crude

72.79 Price
-0.810% 1D Chg, %
Long position overnight fee -0.0224%
Short position overnight fee 0.0005%
Overnight fee time 22:00 (UTC)
Spread 0.030

Gold

2,019.85 Price
-0.550% 1D Chg, %
Long position overnight fee -0.0200%
Short position overnight fee 0.0118%
Overnight fee time 22:00 (UTC)
Spread 0.50

BTC/USD

43,668.25 Price
+3.830% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

15,857.50 Price
+0.130% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading